The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

202154 citationsJournal Articlehybrid Open Access

Authors

Mark W. Skinner · McMaster University

Claude Négrier · Université Claude Bernard Lyon 1

Ido Paz‐Priel

Sammy Chebon · Roche (Switzerland)

Víctor Jiménez‐Yuste · Hospital Universitario La Paz

Michael U. Callaghan · Central Michigan University

Michaela Lehle · Roche (Switzerland)

Abstract

Emicizumab prophylaxis in PwHA without FVIII inhibitors resulted in persistent and meaningful improvements in Haem-A-QoL PH and less work disruption than previous treatment.

Topics & Keywords

Hemophilia Treatment and Research Coagulation, Bradykinin, Polyphosphates, and Angioedema Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Haemophilia

Volume 27, Issue 5, pp. 854-865

DOI: 10.1111/hae.14363

Field-Weighted Citation Impact: 4.82